Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection

Virginia Urquidi, Steven Goodison, Jeongsoon Kim, Myron Chang, Yunfeng Dai, Charles J. Rosser

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To investigate whether elevated urinary levels of vascular endothelial growth factor (VEGF), carbonic anhydrase 9 (CA9), and angiogenin are associated with bladder cancer (BCa). Methods: This was a case-control study in which voided urine samples from 127 patients (63 control subjects and 64 patients with BCa) were analyzed. The urinary concentrations of VEGF, CA9, angiogenin, and bladder tumor antigen (BTA) were assessed using enzyme-linked immunosorbent assays. We used the area under the curve of receiver operating characteristic curves to determine the ability of VEGF, CA9, and angiogenin to detect BCa in voided urine samples. Data were also compared with the findings from a commercial enzyme-linked immunosorbent assay-based BCa detection assay (BTA-Trak). The sensitivity, specificity, and positive and negative predictive values were calculated. Results: The urinary concentrations of VEGF, CA9, angiogenin, and BTA were significantly elevated in those with BCa. VEGF was the most accurate urinary biomarker (area under the curve 0.886, 95% confidence interval 0.8301-0.9418). Furthermore, multivariate regression analysis highlighted VEGF (odds ratio 5.90, 95% confidence interval 2.60-13.40, P <.0001) as an independent variable. The sensitivity and specificity for VEGF (83% sensitivity and 87% specificity) outperformed those for BTA (80% sensitivity and 84% specificity). Conclusion: VEGF could be a valuable addition to voided urine sample analysis for the detection of BCa. Larger, prospective studies are needed to determine the clinical utility of urinary VEGF and angiogenin as biomarkers in the noninvasive evaluation of patients with BCa.

Original languageEnglish (US)
JournalUrology
Volume79
Issue number5
DOIs
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Vascular Endothelial Growth Factor A
Biomarkers
Neoplasm Antigens
Sensitivity and Specificity
Urine
Area Under Curve
angiogenin
Carbonic Anhydrase IX
Enzyme-Linked Immunosorbent Assay
Confidence Intervals
ROC Curve
Case-Control Studies
Multivariate Analysis
Odds Ratio
Regression Analysis
Prospective Studies

ASJC Scopus subject areas

  • Urology

Cite this

Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. / Urquidi, Virginia; Goodison, Steven; Kim, Jeongsoon; Chang, Myron; Dai, Yunfeng; Rosser, Charles J.

In: Urology, Vol. 79, No. 5, 01.05.2012.

Research output: Contribution to journalArticle

Urquidi, Virginia ; Goodison, Steven ; Kim, Jeongsoon ; Chang, Myron ; Dai, Yunfeng ; Rosser, Charles J. / Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. In: Urology. 2012 ; Vol. 79, No. 5.
@article{9a81e921262649a9a3814427711653f0,
title = "Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection",
abstract = "Objective: To investigate whether elevated urinary levels of vascular endothelial growth factor (VEGF), carbonic anhydrase 9 (CA9), and angiogenin are associated with bladder cancer (BCa). Methods: This was a case-control study in which voided urine samples from 127 patients (63 control subjects and 64 patients with BCa) were analyzed. The urinary concentrations of VEGF, CA9, angiogenin, and bladder tumor antigen (BTA) were assessed using enzyme-linked immunosorbent assays. We used the area under the curve of receiver operating characteristic curves to determine the ability of VEGF, CA9, and angiogenin to detect BCa in voided urine samples. Data were also compared with the findings from a commercial enzyme-linked immunosorbent assay-based BCa detection assay (BTA-Trak). The sensitivity, specificity, and positive and negative predictive values were calculated. Results: The urinary concentrations of VEGF, CA9, angiogenin, and BTA were significantly elevated in those with BCa. VEGF was the most accurate urinary biomarker (area under the curve 0.886, 95{\%} confidence interval 0.8301-0.9418). Furthermore, multivariate regression analysis highlighted VEGF (odds ratio 5.90, 95{\%} confidence interval 2.60-13.40, P <.0001) as an independent variable. The sensitivity and specificity for VEGF (83{\%} sensitivity and 87{\%} specificity) outperformed those for BTA (80{\%} sensitivity and 84{\%} specificity). Conclusion: VEGF could be a valuable addition to voided urine sample analysis for the detection of BCa. Larger, prospective studies are needed to determine the clinical utility of urinary VEGF and angiogenin as biomarkers in the noninvasive evaluation of patients with BCa.",
author = "Virginia Urquidi and Steven Goodison and Jeongsoon Kim and Myron Chang and Yunfeng Dai and Rosser, {Charles J.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.urology.2012.01.016",
language = "English (US)",
volume = "79",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection

AU - Urquidi, Virginia

AU - Goodison, Steven

AU - Kim, Jeongsoon

AU - Chang, Myron

AU - Dai, Yunfeng

AU - Rosser, Charles J.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Objective: To investigate whether elevated urinary levels of vascular endothelial growth factor (VEGF), carbonic anhydrase 9 (CA9), and angiogenin are associated with bladder cancer (BCa). Methods: This was a case-control study in which voided urine samples from 127 patients (63 control subjects and 64 patients with BCa) were analyzed. The urinary concentrations of VEGF, CA9, angiogenin, and bladder tumor antigen (BTA) were assessed using enzyme-linked immunosorbent assays. We used the area under the curve of receiver operating characteristic curves to determine the ability of VEGF, CA9, and angiogenin to detect BCa in voided urine samples. Data were also compared with the findings from a commercial enzyme-linked immunosorbent assay-based BCa detection assay (BTA-Trak). The sensitivity, specificity, and positive and negative predictive values were calculated. Results: The urinary concentrations of VEGF, CA9, angiogenin, and BTA were significantly elevated in those with BCa. VEGF was the most accurate urinary biomarker (area under the curve 0.886, 95% confidence interval 0.8301-0.9418). Furthermore, multivariate regression analysis highlighted VEGF (odds ratio 5.90, 95% confidence interval 2.60-13.40, P <.0001) as an independent variable. The sensitivity and specificity for VEGF (83% sensitivity and 87% specificity) outperformed those for BTA (80% sensitivity and 84% specificity). Conclusion: VEGF could be a valuable addition to voided urine sample analysis for the detection of BCa. Larger, prospective studies are needed to determine the clinical utility of urinary VEGF and angiogenin as biomarkers in the noninvasive evaluation of patients with BCa.

AB - Objective: To investigate whether elevated urinary levels of vascular endothelial growth factor (VEGF), carbonic anhydrase 9 (CA9), and angiogenin are associated with bladder cancer (BCa). Methods: This was a case-control study in which voided urine samples from 127 patients (63 control subjects and 64 patients with BCa) were analyzed. The urinary concentrations of VEGF, CA9, angiogenin, and bladder tumor antigen (BTA) were assessed using enzyme-linked immunosorbent assays. We used the area under the curve of receiver operating characteristic curves to determine the ability of VEGF, CA9, and angiogenin to detect BCa in voided urine samples. Data were also compared with the findings from a commercial enzyme-linked immunosorbent assay-based BCa detection assay (BTA-Trak). The sensitivity, specificity, and positive and negative predictive values were calculated. Results: The urinary concentrations of VEGF, CA9, angiogenin, and BTA were significantly elevated in those with BCa. VEGF was the most accurate urinary biomarker (area under the curve 0.886, 95% confidence interval 0.8301-0.9418). Furthermore, multivariate regression analysis highlighted VEGF (odds ratio 5.90, 95% confidence interval 2.60-13.40, P <.0001) as an independent variable. The sensitivity and specificity for VEGF (83% sensitivity and 87% specificity) outperformed those for BTA (80% sensitivity and 84% specificity). Conclusion: VEGF could be a valuable addition to voided urine sample analysis for the detection of BCa. Larger, prospective studies are needed to determine the clinical utility of urinary VEGF and angiogenin as biomarkers in the noninvasive evaluation of patients with BCa.

UR - http://www.scopus.com/inward/record.url?scp=84862794795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862794795&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2012.01.016

DO - 10.1016/j.urology.2012.01.016

M3 - Article

C2 - 22386755

AN - SCOPUS:84862794795

VL - 79

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -